Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
Ninety-eight patients with metastatic breast cancer, heavily pretreated with other agents, were entered in a phase II trial of hexamethylmelamine (HEX). Patients were randomized to receive HEX alone or combined with prophylactic pyridoxine. There was a 2% response rate in 89 partially or fully evaluable patients. Seven percent of these patients developed neurologic toxicity which occurred in the HEX-alone group only.
D000368:Aged; D006585:Altretamine / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D011736:Pyridoxine / Q000627:therapeutic use; D014227:Triazines / Q000627:therapeutic use*
D014227:Triazines; D011736:Pyridoxine; D006585:Altretamine